Intake of coffee, caffeine and other methylxanthines and risk of Type I vs Type II endometrial cancer
Menée sur une cohorte de 23 356 femmes ménopausées (durée de suivi : 20 ans), cette étude prospective évalue, en fonction de l'indice de masse corporelle, l'association entre la consommation de café, de caféine ou d'autres méthylxanthines et le risque de cancer de l'endomètre de type I (471 cas) ou de type II (71 cas)
Background : Coffee and other sources of methylxanthines and risk of Type I vs Type II endometrial cancer (EC) have not been evaluated previously. Methods : Prospective cohort of 23 356 postmenopausal women with 471 Type I and 71 Type II EC cases. Results : Type I EC was statistically significantly associated with caffeinated (relative risk (RR)=0.65 for 4+ cups per day vs less than or equal to1 cup per month: 95% confidence interval (CI): 0.47–0.89) but not decaffeinated (RR=0.76; 95% CI: 0.50–1.15) coffee intake; there were no associations with tea, cola or chocolate, or for Type II EC. The inverse association with caffeinated coffee intake was specific to women with a body mass index 30+ kg m−2 (RR=0.56; 95% CI: 0.36–0.89). Conclusion : Coffee may protect against Type I EC in obese postmenopausal women.